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Abstract
Background: Trachoma is the leading infectious cause of blindness in the world, and for endemic communities, mass
treatment with azithromycin reduces the pool of infection. High coverage is essential, especially in children as they are the
infectious reservoir. However, infection remains post-mass treatment. We sought to determine risk factors for infection in
children post-mass treatment.
Methodology: All children under 9 years in 4 villages in Tanzania were followed from baseline pre-mass treatment to six
months post treatment. 1,991 children under nine years were enrolled in the longitudinal study and data on individual and
household characteristics was collected at baseline. Clinical trachoma was determined by an ocular exam and infection
detected by PCR of an eyelid swab. Azithromycin was offered and infection was reassessed at 6 months. A multilevel logistic
regression model was used, accounting for household clustering of children for analysis.
Principal Findings: Baseline infection was 23.7% and at 6 months was 10.4%, despite 95% coverage. Infection at baseline
was positively associated with infection at 6 months (OR=3.31, 95%CI 2.40–4.56) and treatment had a protective effect
(OR=0.45, 95%CI 0.25–0.80). The age group 2–4 years had an increased risk of infection at 6 months. The household
characteristics predictive of infection at 6 months were increasing number of children infected in the household at baseline
and increasing number of untreated children in the household.
Conclusions: While one round of mass treatment with high coverage did decrease infection by over 50%, it appears that it is
not sufficient to eliminate infection. Findings that young children (ages 2–4 years) and households with increasing numbers
of infected and untreated children have a positive association with infection at 6 months suggest that such households
could be targeted for more intensive follow up.
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Introduction
Trachoma is a blinding chronic conjunctivitis caused by
repeated episodes of ocular Chlamydia trachomatis infection. It
continues to be the leading infectious cause of blindness in the
world, largely in the most resource poor countries [1]. The World
Health Organization (WHO) has made a commitment to
eliminate blinding trachoma by the year 2020 (Global Elimination
of Blinding Trachoma) [2]. The strategy designed for this initiative
can be summarized with the acronym, SAFE, Surgery for
trichiasis, Antibiotic to reduce the community pool of C. trachomatis
infection, Facial cleanliness, and Environmental change to reduce
transmission.
In 1999, a study by Schachter et al. demonstrated that
azithromycin could be effective in a mass treatment campaign to
reduce the infection in endemic villages. The manufacturer has
since provided the drug free of charge to trachoma endemic
countries that apply for donation [3]. Eliminating infection with a
single dose of antibiotic is very appealing, because of improved
compliance. In theory, infection could potentially be eliminated
from a population in a single effort. This has been reported in
some villages that have low trachoma prevalence [4].
However, in hyper-endemic villages, infection is still found in
treated children following mass treatment. The biggest reservoir of
active disease and infection is seen in children [5]. Two months
after mass treatment of a hyper-endemic village in Tanzania, more
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continued to be infected [6]. In hyper-endemic villages, where
active trachoma may be as high as 50% in children in cross
sectional surveys, it has been suggested that up to 6 rounds of mass
treatment may be necessary to eliminate infection [7].
In order to further investigate infection following mass
treatment, we sought to determine the household and child
factors that predict infection post treatment. Identifying such
factors could help determine how to implement mass treatment.
Methods
Procedures
At the beginning of 2009 a household census was performed in
4 villages in Kongwa district, Tanzania. Children less than 9 years
of age were identified and their parents were invited to have their
children participate in a longitudinal study of trachoma and
infection over a three year period. Written informed consent was
obtained from all parents or guardians of children in this study. All
procedures for the study were approved by the Johns Hopkins
University Institutional Review Board (JHU IRB) and the
National Institute of Medical Research (NIMR) in Tanzania.
Data on the potential risk factors at the individual and
household levels were collected at baseline. The individual
characteristics included age, gender, active trachoma and presence
of Chlamydia trachomatis at baseline, and facial cleanliness in
children 5 years of age and younger. The household characteristics
were: distance to the nearest source of water (measured as self
report of the time to walk one way), presence of a latrine as
observed by the interviewer at the household, and average years of
education of the head of the household based on self report. Facial
cleanliness was assessed on children ages five years and younger by
direct observation, using three elements: presence of ocular or
nasal crusting, and observation of one or more flies on the face in a
three second window, as measured at the time of the exam [8].
Active trachoma and presence of C. trachomatis were also
determined at 6 months.
Trained trachoma graders performed an ocular exam using
2.5x loupes and a torch to determine active trachoma. The
trachoma graders were standardized during a two week training
exercise prior to the start of the study. Inter-observer agreement,
and agreement with a senior grader had to be above kappa=0.6
for TF and TI. Graders are monitored every six months by
comparison of grades against the senior grader using a series of
trachoma images [9]. Active trachoma was graded using the
World Health Organization simple grading scheme [10].
An eyelid-conjunctival swab was obtained to assess presence of
C. trachomatis DNA. These swabs were taken using strict protocols
to avoid contamination. Both the trachoma grader and eyelid
flipper used gloves and changed them between each child
examined. In addition, ‘‘air control’’ swabs were taken on a
random sample of 5% of children. The swabs were waved in the
air above the child and not touched to the eyelid, marked as per
any other sample and sent for processing. If positive, further
investigation were carried out to determine the source of
contamination. The samples were kept at 220uC until they were
sent to the International Chlamydia Laboratory at Johns Hopkins
University for processing. The samples were analyzed using real-
time Polymerase Chain Reaction (Amplicor: Roche Molecular
Systems, Indianapolis, IN) according to manufacturer’s directions.
Optical density was used to identify positive results and defined as
.0.7. Optical densities between 0.2 and 0.7 were considered
equivocal and were retested. Dummy swabs were performed to
test for contamination in the field and laboratory. Results of
dummy swabs showed evidence of lab contamination that affected
34 samples at baseline. Contaminated samples were excluded; all
further tests for contamination were negative at baseline and
follow up.
A single dose of azithromycin at a dose of 20 mg/kg up to 1 g
was offered to all residents 6 months of age and older in each of
the 4 villages by community treatment assistants, who observed
and recorded treatment. Infants under 6 months of age were
treated using topical tetracycline (6 weeks of 1% tetracycline
Author Summary
Trachoma control programs aim for high coverage of
endemic communities with oral azithromycin to reduce
the pool of infection with Chlamydia trachomatis. Howev-
er, even with high coverage, infection is seen following
treatment. In four communities in Tanzania, we followed
every child aged under ten years from baseline through
treatment to six months post-treatment. We determined
who had infection at baseline and who still had or
developed infection six months later. Coverage was over
95% in children in these communities, and infection in
these children decreased by over 50% at six months. The
study found that, at baseline, uninfected children who
were treated had prevalence of infection at 6 months of
6%, but infected children who were treated had preva-
lence of infection of 22% at 6 months. Other risk factors for
infection at 6 months included living in a household with
other infected children, and living in a household with
untreated children. Our data suggest that households with
untreated children might be targeted for more intensive
follow up to increase coverage and reduce subsequent
infection in the community.
Figure 1. Sample population.
doi:10.1371/journal.pntd.0000978.g001
Table 1. Baseline characteristics of the 1991 children in the
study sample vs. 161 children who had no data at 6 months.
Missing at 6
Months Study Sample P**
% Active Trachoma 27.3 27.8 0.9
% PCR Infection* 21.7 23.7 0.57
% Unclean Faces 51.3 51.7 0.9
Age (mean) 3.9 4.0 0.54
% Female 48.4 50.9 0.55
% Treated 87.5 95.0 0.0001
*34 children had unusable PCR at baseline.
**chi square tests and a t-test for difference in mean ages.
doi:10.1371/journal.pntd.0000978.t001
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time of the baseline assessment.
Statistical Analysis
Contingency table analysis was used to identify factors
associated with infection at six months, corresponding p-values
were obtained from a logistic model with infection at 6 months as
the outcome, accounting for clustering at the household level. In
the multivariate stage, logistic regression was used to model
presence of infection at six months as a function of the factors
found to be associated at a 0.15 level in the univariate analysis, a
backward elimination strategy was used to find a parsimonious
model. Among variables whose p-value was greater than 0.05, we
deleted the one that had the highest p-value. We proceeded
Table 2. Baseline Characteristics of the Cohort and percentage infected at 6 months.
Baseline Characteristics N % Infected at 6 Months p-value &
Gender
Male 978 9.81 0.42
Female 1012 11.0
Age
,2 473 9.09 REF
2–4 652 14.1 0.006
5–9 865 8.32 0.60
Infection*
Yes 463 23.1 ,0.0001
No 1493 6.43
Treated
Yes 1891 9.78 0.002
No 99 22.2
Child age 0–5 with clean face at baseline**
Yes 644 10.1 0.10
No 690 12.9
Number of infected children in the household at baseline***:
0 1395 7.2
1 334 15.3 ,0.001
2 146 27.7
3+ 81 28.4
Number of untreated children in the household***
0 1858 9.6 0.02#
1 98 19.4
2+ 36 25.0
Other Children with TF and/or TI in HH at baseline***
Yes 403 14.9 0.002
No 1587 9.3
Resident of a household.60 minutes from water source
Yes 1486 11.1 0.15
No 504 8.3
Resident a household with Latrine
Yes 1336 10.9 0.38
No 654 9.3
Education of head of household ****
None 1044 10.9 REF
Less than primary (1–6) 151 6.6 0.11
Primary or more (7–12) 791 10.4 0.70
*34 specimens were unusable at baseline
**Only children in this age group had assessment of facial cleanliness at baseline.
***the number reflects other children in household infected/having clinical disease/not treated, not counting the index child
****4 households missing information
&From a logistic model with infection at 6 months as the outcome accounting for clustering at the household level,
#linear trend.
doi:10.1371/journal.pntd.0000978.t002
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less than 0.05. The generalized estimating equation (GEE)
approach was used to correct the standard errors to account for
the correlation among children members of the same house
(procedure GENMOD in SAS, binomial distribution, logit link
function, exchangeable correlation structure).
Results
There were a total of 2201 children less than 9 years of age in
the four villages at the time of census (Figure 1). A total of 49
(2.2%) of the children did not participate in the study at baseline.
An additional 161 (7.5%) did not return at 6 months for the ocular
exam. Thus, our study population consisted of 1991 children with
collected data at baseline and 6 months.
A comparison of baseline characteristics of the study population
and the 161 children who missed the 6-month ocular exam revealed
no significant differences for all characteristics except treatment
(Table 1). The study population had antibiotic coverage of 95.0%
while the children with missing 6 month data had 87.5% coverage,
reflectingthe fact that some of them leftthe study even prior to mass
treatment. Of note, the baseline prevalence of infection in study
children was 24% compared to 22% in those who did not
participate at 6 months, a non-significant difference. Overall the
prevalence of Chlamydia infection and active trachoma respectively
were 23.7% and 27.8% in the study population at baseline.
At 6 months, 203 children were infected (10.4%), down from
23.7% at baseline. Characteristics associated with infection at 6
months are shown in table 2. There was no difference in infection
at 6 months by gender or those with clean or unclean faces at
baseline or the available household characteristics (education,
distance to water, presence of a latrine). Prevalence of infection at
6 months were higher in those 2–4 years of age, with baseline
infection, and in the untreated group (Table 2). Children were
more likely to be infected at 6 months if other children in the
household were infected at baseline (7%, 15%, 28% for 0, 1, 2+
infected children, test for trend p=0.001). In addition the risk of
infection increased with the number of untreated children in the
same household (test for trend p=0.02).
The effect of treatment seemed to be different depending on the
infection status at baseline (Table 3). Among infected children,
children who were treated at baseline had 6–month prevalence of
infection of 22.0%, compared to 5.9% in uninfected children who
were treated. Children who were untreated and infected at
baseline had a 3.1-fold higher chance of being infected at 6 months
compared to untreated and uninfected children, 50.0% vs. 16.0%.
However, after adjusting for other factors the interaction between
infection at baseline and the effect of treatment was not statistically
significant (p=0.59).
Table 3. Interaction of baseline infection and treatment, and
infection at 6 months**.
N
% infected at 6
months P***
Not Infected at baseline*
Treated at baseline 1,412 5.9 0.001
Not treated at baseline 81 16.0
Infected at baseline*
Treated at baseline 445 22.0 0.09
Not treated at baseline 18 50.0
*34 specimens were unusable at baseline.
**Interaction of treatment and baseline infection status, adjusted for age and
clustering at household level, was not significant, p=.59.
***From a logistic model with infection at 6 months as the outcome accounting
for clustering at the household level.
doi:10.1371/journal.pntd.0000978.t003
Table 4. Baseline characteristics of the sub group of 1439 children who were not infected at baseline, and infected at 6 months
(n=96).
Baseline Characteristics N % Infected at 6 Months P***
Gender
Male 738 6.50 0.91
Female 755 6.36
Age
,2 392 6.63 REF
2–4 464 7.32 0.68
5–9 637 5.65 0.53
Treated
Yes 1412 5.88 0.003
No 81 16.0
Child age 0–5 with clean face at baseline *
Yes 495 6.67 0.99
No 498 6.62
Other Children infected in household at baseline:**
Yes 261 7.66 0.45
No 1232 6.17
*Only children in this age group had assessment of facial cleanliness at baseline.
**The number reflects other children in household infected, not counting the index child.
***From a logistic model with infection at 6 months as the outcome accounting for clustering at the household level.
doi:10.1371/journal.pntd.0000978.t004
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6.4% were infected at 6 months. In this sub group, treatment was
the only explanatory factor comparing those who stayed free of
infection with those 96 who developed infection at 6 months.
Among those free of infection, 95.1% had been treated compared
to 86.4% of those who developed infection. We found no
difference in gender, mean age, percentage of children under 5
years of age with unclean faces, or whether at baseline there was
another infected child in the house (Table 4).
Our final model predicted infection at 6 months, adjusted for
multiple variables and household clustering (Table 5). Factors that
independently increased the odds of having infection at 6 months
included being in the age group 2–4 years old (OR=1.41), having
infection at baseline (OR=3.31), and living in a household with
other infected children (OR=1.39 per additional infected child).
Treatment significantly reduced the odds of infection at 6 months
(OR=0.45), and other untreated children in the household were
associated with increased risk (OR=1.58 per additional untreated
child).
Discussion
In these four endemic communities we found an overall
prevalence of Chlamydia infection at baseline of 23.7%. Mass
antibiotic treatment coverage reached 95% of the children in the
population, which is close to a goal of full coverage of all children.
Despite such high coverage, the infection at 6 months was 10.4%.
One factor that predicted infection at 6 months was infection at
baseline. This is consistent with a similar finding in a study from
another village with similar endemicity in Tanzania [6] [11]. At six
months, these infections may be due to lack of treatment, although
with high coverage these are few case; the infections may also be
due to high bacterial loads in those treated, which made them less
likely to be cured after a single dose. West et al found previously
that those children with the highest bacterial load pre-treatment
were most likely to still have infection 2 months after treatment
[6]. Potentially, the dose of azithromycin could be increased for
these children, but a randomized trial of 30 mg/kg versus 20 mg/
kg dose in children with severe trachoma did not demonstrate any
difference in outcome [12]. Recent data from Ethiopia suggests
that more frequent treatment, perhaps every six months, would be
more effective, although this needs to be confirmed [7]. The
feasibility for programs of implementing treatment even every six
months to families of young children would need careful study of
the cost-effectiveness of such a strategy, as it would likely double
the yearly costs of mass treatment as well as demand for
azithromycin.
Another factor associated with infection at 6 months, indepen-
dent of self-infection at baseline, was the number of children
infected in the household at baseline, and number of untreated
children in the household. This finding is not unexpected, as some
of the infected siblings may well be the source of reinfection [13].
To the extent that not all children are treated in the household
leaves a risk for other members, as intra-household transmission
appears to be relatively fast [11,13]. Another study has shown that
missing treatment does not occur at random, but clusters in
households, suggesting that finding households that are non
participants in mass treatment, and determining strategies to
improve coverage in that group may be needed [14].
Finally, the 2–4 year age group was at increased risk of infection
post-mass treatment, independently of treatment status or
infection status. We did not collect data on bacterial load and it
is possible that this particular age group has the highest load of
infection, thus most likely to remain infected post treatment. We
expected the highest prevalence of infection at 6 months would be
the infants who had to be treated with topical tetracycline, and for
whom compliance with a six-week course could not be assured.
However, infection post treatment was greatest in the 2–4 year
olds, and there was no association of 6 month infection with
having an infant or infected infant in the household.
One limitation to our study is that we were not able to measure
chlamydial load. Thus, we cannot be certain if this is the reason
that the children ages 2–4 had higher odds of infection at 6
months. Another potential limitation is loss to follow-up of
children in the study. There are two points at which we lost
subjects from our original eligible population. The first was at the
start of the study, where 49 (2.1%) of children did not participate.
This is a small number compared to the total size of the population
and is unlikely to bias our results. The second point was at the 6-
month follow-up visit, where 161 (7.3%) children did not return
for a follow up exam. There were no differences in baseline
characteristics between the 1991 children in the study sample and
Table 5. Multivariate logistic regression model predicting infection at 6 months*.











Number of Infected Children in household (per child) 1.39 1.18–1.64
Number of untreated children in household (per child) 1.58 1.08–2.31
*adjusted for clustering of children in the households.
doi:10.1371/journal.pntd.0000978.t005
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receiving antibiotics. Thus, they may have been more likely to
have infection at 6 months, but this would not be expected to bias
our findings as they were no more likely to have infection at
baseline. In addition, 34 of the 1991 samples (1.7%) at baseline
could not be used. It is unlikely that this loss contributed to bias as
the number lost was so small, and was the result of error in the
laboratory, which is masked to any clinical or treatment data.
In summary, although we found that village coverage with
azithromycin decreased infection at 6 months in children ages 9
and under, it did not eliminate the pool of infection. Clearly, one
round of mass treatment in these communities with infection
above 20% is not enough. Based on these findings, which support
our previous findings in a single community, mass treatment of
communities should be continued as part of the SAFE strategy to
eliminate blinding trachoma. The World Health Organization
recommends at least three annual mass treatment interventions as
part of SAFE, and our study will provide data in the future on
potential re-emergence following a second and third round of mass
treatment in line with those recommendations [15].
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